Holen Sie sich die Stockscreener-App
74.38
3.18%
2.29
Handel nachbörslich:
74.35
-0.03
-0.04%
Schlusskurs vom Vortag:
$72.09
Offen:
$72.5
24-Stunden-Volumen:
834.67K
Relative Volume:
0.91
Marktkapitalisierung:
$12.87B
Einnahmen:
$8.31B
Nettoeinkommen (Verlust:
$379.00M
KGV:
34.44
EPS:
2.16
Netto-Cashflow:
$385.00M
1W Leistung:
+2.49%
1M Leistung:
+0.79%
6M Leistung:
+0.09%
1J Leistung:
+27.76%
1-Tages-Spanne:
$72.12
$74.44
1-Wochen-Bereich:
$71.34
$74.98
52-Wochen-Spanne:
$57.48
$85.92
Solventum Corp Stock (SOLV) Company Profile
Firmenname
Solventum Corp
Sektor
Telefon
651-733-1110
Adresse
C/O 3M COMPANY, ST. PAUL
Vergleichen Sie SOLV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SOLV
Solventum Corp
|
74.38 | 12.50B | 8.31B | 379.00M | 385.00M | 2.16 |
|
ISRG
Intuitive Surgical Inc
|
482.35 | 171.42B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
195.96 | 55.88B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
86.48 | 42.55B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
288.28 | 41.48B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
246.22 | 17.25B | 2.90B | 467.20M | 306.90M | 6.37 |
Solventum Corp Stock (SOLV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Argus | Hold → Buy |
| 2025-06-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-05-19 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-07 | Eingeleitet | Piper Sandler | Neutral |
| 2024-09-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-09-05 | Eingeleitet | BTIG Research | Neutral |
| 2024-06-24 | Eingeleitet | Argus | Hold |
| 2024-05-30 | Eingeleitet | Goldman | Sell |
| 2024-05-10 | Eingeleitet | BofA Securities | Neutral |
| 2024-04-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-04-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-04-02 | Eingeleitet | Edward Jones | Hold |
Alle ansehen
Solventum Corp Aktie (SOLV) Neueste Nachrichten
Solventum announces launch of secondary offering of common stock - MSN
Solventum Announces Secondary Offering of 8.8 Million Shares by 3M - MarketScreener
Solventum stock falls after 3M announces secondary offering By Investing.com - Investing.com Nigeria
Solventum's Secondary Offering: A Balancing Act Between Liquidity and Dilution - AInvest
Solventum stock falls after 3M announces secondary offering - Investing.com
3M to sell 8.8 million shares of Solventum in secondary offering - Investing.com
Solventum Announces Launch of Secondary Offering of Common Stock - PR Newswire
Solventum Corporation (SOLV) Reports Q2 2025 Results; Mizuho and Wells Fargo Reiterate Their Ratings - Yahoo Finance
Solventum ups financial guidance as tariff risks fade - MSN
Steris, Solventum upgraded, RxSight downgraded in Morgan Stanley's MedTech review - MSN
How Is Solventum's Stock Performance Compared to Other Health Care Equipment Stocks? - MSN
Research Alert: CFRA Maintains Hold Opinion On Shares Of Solventum Corporation - 富途牛牛
Will Strong Q2 Results and Raised Outlook Change Solventum's (SOLV) Narrative? - simplywall.st
Solventum raises annual profit forecast on strength in surgical equipment - MSN
Piper Sandler Boosts Solventum (NYSE:SOLV) Price Target to $94.00 - MarketBeat
Should Solventum's (SOLV) Earnings Upgrade and Revenue Growth Prompt Portfolio Reassessment by Investors? - simplywall.st
Solventum 2025 Q2 Earnings Net Income Rises 1.1% - AInvest
Stock Analysis | Solventum OutlookNavigating Mixed Signals Amid Weak Technicals - AInvest
Solventum Q2 FY25 slides reveal improved performance and increased full-year outlook - Investing.com Canada
Solventum Exceeds 2Q25 Expectations with $2.16B Revenue, Reduces Tariff Impact - Medical Device and Diagnostic industry
Goldman Sachs Adjusts Solventum Price Target to $73 From $71, Maintains Sell Rating - MarketScreener
Solventum Stock Gains on Q2 Earnings & Revenue Beat, Margins Improve - The Globe and Mail
Solventum Stock Gains On Q2 Earnings & Revenue Beat, Margins Improve - Barchart.com
Solventum raises 2025 EPS guidance to $5.80-$5.95 with sales growth outlook up to 3% as transformation gains momentum - MSN
Solventum Boosts Annual Profit Outlook on Surging Medical Device DemandNews and Statistics - IndexBox
Solventum stock price target raised to $94 by Piper Sandler on strong Q2 - Investing.com Nigeria
Solventum price target raised to $94 from $87 at Piper Sandler - TipRanks
Solventum rises after lifting annual profit forecast - TradingView
Solventum Raises EPS Guidance to $5.80-$5.95, Sales Growth Outlook Up to 3% Amid Transformation Gains - AInvest
Earnings call transcript: Solventum’s Q2 2025 earnings beat expectations - Investing.com
Earnings call transcript: Solventum’s Q2 2025 earnings beat expectations By Investing.com - Investing.com UK
Solventum: Q2 Earnings Snapshot - Connecticut Post
Morgan Stanley Upgrades Solventum (SOLV) on Growth Potential - MSN
Solventum Corp SEC 10-Q Report - TradingView
Solventum Q2 FY25 slides reveal improved performance and increased full-year outlook By Investing.com - Investing.com South Africa
Solventum 2025 Q2 Earnings Positive Earnings Growth with Raised Guidance - AInvest
Solventum (SOLV) Fiscal Q2 EPS Jumps 8% - AOL.com
Solventum Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Solventum (SOLV) Q2 2025 Earnings Call Transcript - Fortune
Solventum (SOLV) Reports Earnings Tomorrow: What To Expect - MSN
Solventum (SOLV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Transcript : Solventum Corporation, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Solventum (SOLV) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Solventum shares surge as raised guidance tops expectations By Investing.com - Investing.com South Africa
Solventum shares surge as raised guidance tops expectations - Investing.com
Solventum reports Q2 adjusted EPS $1.69, consensus $1.45 - TipRanks
Solventum raises annual profit forecast on strength in surgical equipment By Reuters - Investing.com
Solventum Corporation Q2 Sales Increase - Nasdaq
Finanzdaten der Solventum Corp-Aktie (SOLV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):